Generex cancer, drug delivery news

Generex provided an update on its plans to spin out its wholly-owned subsidiary, Antigen Express Inc., and said several merger opportunities, including shell companies and operating biotechs with synergistic properties, are being reviewed. The spinout is expected to occur this year or early next year with a fundraising to follow. If a merger and initial fund raising are successful, Generex will seek a listing for the merged company on a national exchange. Generex said it will issue at least one stock dividend of Antigen Express stock to Generex stockholders and expects to retain a controlling interest in the subsidiary (see BioCentury, April 4). ...